سعر ديكونادال 20 مجم 21 قرص مغلف 2024

Deconadal 20 mg 21 f.c. tabs.: Rosuvastatin (Copad pharma).

• Adjunct to diet to reduce elevated LDL-C, total-C, ApoB, non-HDL-C, TG and to increase HDL-C in primary hyperlipidemia and mixed dyslipidemia; primary prevention of CV disease in patients at risk (CRESTOR US label scope).DailyMed (U.S. National Library of Medicine)

• Common: headache, nausea, myalgia, asthenia, constipation, abdominal pain. Serious: myopathy, rhabdomyolysis, hepatotoxicity, hypersensitivity.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis; hypersensitivity to rosuvastatin.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Myopathy/rhabdomyolysis (risk ↑ with age ≥65, uncontrolled hypothyroidism, renal impairment, higher doses, interacting drugs). Immune-mediated necrotizing myopathy. Hepatic dysfunction — check LFTs. Increases in HbA1c/fasting glucose. Proteinuria/hematuria. Rare interstitial lung disease reports with some statins.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Cyclosporine / gemfibrozil / certain antivirals / colchicineMajorIncreased rosuvastatin exposure and myopathy risk with cyclosporine, gemfibrozil, some protease inhibitors/HCV regimens, and colchicine; dose limits or avoidance per label.DailyMed (U.S. National Library of Medicine)
• WarfarinModerateMay increase INR; monitor anticoagulation when starting/changing rosuvastatin dose.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognized; cholesterol biosynthesis is important for fetal development. Statins are generally contraindicated in pregnancy.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Rosuvastatin may be present in human milk; breastfeeding not recommended during treatment (US label).General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Rosuvastatin: Competitive inhibition of HMG-CoA reductase reduces hepatic cholesterol synthesis and increases LDL-receptor expression.